LILRB1 and Miyoshi myopathy: Additionally, treatment with RSL3 in NSG mice did not significantly affect the tumor burden of CTR-KD ARP-1 cells; however, it inhibited MM progression in mice bearing LILRB1-KD ARP-1 cells (Supplementary Fig. 3n–p).